MLICM
IMRX icon

Metropolitan Life Insurance Company (MetLife)’s Immuneering IMRX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,167
Closed -$8.58K – 2322
2023
Q4 		$8.58K Hold
1,167
– – ﹤0.01% 2226
2023
Q3 		$8.96K Hold
1,167
– – ﹤0.01% 2255
2023
Q2 		$11.8K Buy
+1,167
New +$11.2K ﹤0.01% 2213
2021
Q4 		– Sell
-2,814
Closed -$74.7K – 2805
2021
Q3 		$74.7K Buy
+2,814
New +$75.6K ﹤0.01% 2671

Other funds holding IMRX

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HS
HighVista Strategies Boston, Massachusetts $362M AUM 230.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s IMRX Position: Q1 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Immuneering (IMRX) in Q1 2024, closing a stake of 1,167 shares — an estimated $8.58K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in IMRX in Q3 2021 and held it in 4 quarters. The position peaked at $74.7K in Q3 2021. 51 funds tracked by Wall St. Rank hold IMRX as of Q1 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Immuneering position as of Q1 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 1,167 Immuneering shares in Q1 2024, an estimated $8.58K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Immuneering in Q3 2021 and held it in 4 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Immuneering position peaked at $74.7K in Q3 2021.
  • 51 funds tracked by Wall St. Rank held Immuneering as of Q1 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q1 2024, filed 14 May 2024.